JDRF | Jotup

Q2 Named a 2023 Top Workplaces USA Winner

Retrieved on:

Wednesday, February 1, 2023

Q2 Holdings, Inc. (NYSE:QTWO), a leading provider of digital transformation solutions for banking and lending, today announced it once again received the 2023 Top Workplaces USA award, issued by Energage .

Key Points:

Q2 Holdings, Inc. (NYSE:QTWO), a leading provider of digital transformation solutions for banking and lending, today announced it once again received the 2023 Top Workplaces USA award, issued by Energage .
This is the second year for Top Workplaces USA, built on the program’s 16-year history surveying more than 20 million employees across 60 markets for the regional Top Workplaces awards.
“At Q2, our mission is to build strong and diverse communities by strengthening their financial institutions,” said Matt Flake, Q2’s chief executive officer.
The initiative allows non-profits to apply for grants from Q2, and in 2021, Q2 awarded s $10,000 grant to 12 organizations from around the world.

Barrett-Jackson Supercharges Collector Car Hobby in Scottsdale, Exceeds $190.6 Million in Total Auction Sales With 100 Percent No Reserve Docket and More Than 200 World Auction Records

Retrieved on:

Monday, January 30, 2023

In dynamic and trendsetting fashion, the historic event featured a diverse docket of 1,907 No Reserve collectible vehicles totaling more than $184.2 million in auction sales and surpassing 200 world auction records.

Key Points:

In dynamic and trendsetting fashion, the historic event featured a diverse docket of 1,907 No Reserve collectible vehicles totaling more than $184.2 million in auction sales and surpassing 200 world auction records.
Over 1,100 pieces of authentic automobilia were also auctioned for more than $6.41 million, bringing total auction sales above $190.6 million.
View the full release here: https://www.businesswire.com/news/home/20230130005700/en/
Barrett-Jackson featured a diverse docket of 1,907 No Reserve collectible vehicles totaling more than $184.2 million in auction sales and surpassing 200 world auction records.
“We saw a spectacular docket bring incredible sales and set more than 200 world auction records.

Tidepool Announces FDA Clearance of Tidepool Loop

Retrieved on:

Tuesday, January 24, 2023

Tidepool, a 501(c)3 nonprofit committed to empowering the next generation of innovations in diabetes management, today announced the FDA clearance of Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes (T1D) in persons six years of age and greater.

Key Points:

Tidepool, a 501(c)3 nonprofit committed to empowering the next generation of innovations in diabetes management, today announced the FDA clearance of Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes (T1D) in persons six years of age and greater.
View the full release here: https://www.businesswire.com/news/home/20230124006085/en/
Image of Tidepool Loop interface on iPhone and Apple Watch (Graphic: Business Wire)
Tidepool Loop, a patient-led project, is the first application of its kind to receive clearance from the FDA, and is also the first to enable insulin delivery from a compatible Apple Watch.
“We knew this day would come, but we couldn’t have achieved it without the support of the entire diabetes community, including the FDA,” said Howard Look, CEO and co-founder of Tidepool.
We look forward to continuing to work with Tidepool to make open protocol a reality, and we anxiously await news on future AID systems that will utilize this tremendous platform.”
With the clearance of Tidepool Loop, the organization is now finalizing agreements with device partners to create a seamless experience for both physicians prescribing Tidepool Loop and the patients using it.

Select Harris Teeter stores host Health Partner Round Up Campaign

Retrieved on:

Wednesday, January 25, 2023

AHA, Muscular Dystrophy Association, American Heart Association, MDA, Cardiovascular disease, ACS, Partnership, Cancer, American Cancer Society, Outer Banks, Organization, JDRF, Research, Pharmaceutical industry

MATTHEWS, N.C., Jan. 25, 2023 /PRNewswire-PRWeb/ -- Harris Teeter announced today the launch of its Health Partner Round Up Campaign to benefit leading health non-profit organizations, including American Cancer Society (ACS), American Heart Association (AHA), JDRF, Muscular Dystrophy Association (MDA) and former Carolina Panther Greg Olsen's foundation, the HEARTest Yard.

Key Points:

MATTHEWS, N.C., Jan. 25, 2023 /PRNewswire-PRWeb/ -- Harris Teeter announced today the launch of its Health Partner Round Up Campaign to benefit leading health non-profit organizations, including American Cancer Society (ACS), American Heart Association (AHA), JDRF, Muscular Dystrophy Association (MDA) and former Carolina Panther Greg Olsen's foundation, the HEARTest Yard.
Now through April 4, 2023, shoppers can round up their transaction to the nearest whole dollar at all stores, excluding the Outer Bank and Hampton Roads locations, to benefit ACS, AHA, JDRF, MDA.
North Carolina and South Carolina stores will benefit the HEARTest Yard in addition to ACS, AHA, JDRF, and MDA.
The funds collected throughout the campaign will be evenly distributed among the health charity partners.

OneCause Rings in New Year With $5 Billion Raised by Nonprofits

Retrieved on:

Tuesday, January 24, 2023

Big Brothers Big Sisters, Playhouse, Arthritis Foundation, Health, Consultant, American Lung Association, Growth, JDRF, Face, Organization, Big Brothers Big Sisters of America, Education, Management, Video game

INDIANAPOLIS, Jan. 24, 2023 /PRNewswire/ -- OneCause, a leading provider of digital fundraising technology, starts 2023 by celebrating a major milestone: since the company's founding, nonprofit customers have collectively raised over $5 billion for their missions using the company's fundraising software. During this time, over 55,000 campaigns have been hosted on the fundraising platform, advancing causes like health and human services, animal welfare, human rights, education, and youth development.

Key Points:

"At OneCause, we feel a shared sense of responsibility to help nonprofits build better tomorrows," said Steve Johns, chief executive officer of OneCause.
OneCause changed the face of fundraising auctions fifteen years ago when it launched one of the first mobile bidding solutions for nonprofits, then called BidPal.
To date, more than 10,000 nonprofits have partnered with OneCause for their event and online fundraising initiatives.
The $5 billion milestone comes after a year of innovation and growth at the company, during which OneCause customers raised over $1 billion dollars for their causes in 2022 alone.

David Hoffmann, Founder and Chairman of the Hoffmann Family of Companies, to Receive 2023 Horatio Alger Award

Retrieved on:

Wednesday, January 18, 2023

WASHINGTON, D.C., Jan. 18, 2023 /PRNewswire/ -- Horatio Alger Association of Distinguished Americans, Inc., a nonprofit educational organization honoring the achievements of outstanding individuals and encouraging youth to pursue their dreams through higher education, today announced that David Hoffmann, founder and chairman of the Hoffmann Family of Companies, has been selected for membership in this prestigious organization. Mr. Hoffmann joins 12 other exceptional business, civic and cultural leaders from across North America in receiving 2023 honors. For 76 years, the Horatio Alger Award has been annually bestowed upon esteemed individuals who have succeeded despite facing adversities, and who have remained committed to education and charitable efforts in their communities.

Key Points:

Marrying his high school sweetheart, Jerri and David Hoffmann recently celebrated their 50th wedding anniversary, raising three children and 12 grandchildren.
"Each year, it is our utmost honor to present outstanding leaders who have displayed extraordinary perseverance in overcoming challenges with the Horatio Alger Award," said James F. Dicke II, chairman, Horatio Alger Association and 2015 Horatio Alger Award recipient.
Mr. Hoffmann and the Member Class of 2023 will be formally inducted into the Association during the Horatio Alger Award Induction Ceremonies in Washington, D.C. from March 30 through April 1, 2023.
For more information about Horatio Alger Association and its Member Class of 2023, please visit www.horatioalger.org and follow the organization on Facebook , Twitter and Instagram .

Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF

Retrieved on:

Wednesday, January 11, 2023

Therapy, Indiana University School of Medicine, JDRF, Urine, AUC, Fasting, T1D, Patient, Indiana University, Research, Eflornithine, MSN, Phase, Doctor of Philosophy, Food, Pharmaceutical industry

Indiana University expects to enroll 70 patients in the Phase II clinical trial at approximately 6 centers in the United States.

Key Points:

Indiana University expects to enroll 70 patients in the Phase II clinical trial at approximately 6 centers in the United States.
Study eligibility will be for patients with recent onset type 1 diabetes.
“We are pleased to begin the Phase II trial for CPP-1X-T with Indiana University and JDRF, the leading global organization advancing life-changing breakthroughs for type 1 diabetes (T1D),” said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela.
We are excited to move forward with the Phase II Trial, along with Indiana University and JDRF, to provide better treatment options for this patient population.”

Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany

Retrieved on:

Wednesday, December 21, 2022

This automated insulin delivery system (AID) solution is now available in Germany and will be available in additional European countries beginning in 2023.

Key Points:

This automated insulin delivery system (AID) solution is now available in Germany and will be available in additional European countries beginning in 2023.
Nearly five healthy years could be restored if they had access to devices that monitor glucose and automate insulin delivery.
"Technological innovations, like automated insulin delivery systems, can ease some of that uncertainty by continuously monitoring a person's glucose levels and delivering the right insulin dosage, which can ultimately improve time in range.
In addition to partnering with Ypsomed and CamDiab, Abbott is working to make the FreeStyle Libre platform interoperable with other leading insulin delivery systems.

Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis

Retrieved on:

Wednesday, December 14, 2022

Our work to date developing ABA-101 validates our approach of using TCR-targeted Treg therapies to treat autoimmune diseases.

Key Points:

Our work to date developing ABA-101 validates our approach of using TCR-targeted Treg therapies to treat autoimmune diseases.
At ElevateBio, we enjoy collaborating with scientific innovators like Abata, helping power their novel cell and gene therapies, said Michael Paglia, M.S., chief operating officer, ElevateBio BaseCamp.
The hypothesis for ABA-101 as a Treg treatment for progressive MS is firmly rooted in the scientific literature.
ABA-101 is Abatas autologous Treg therapy in development for the treatment of progressive MS.

Abata Therapeutics Appoints Ellen Cahir-McFarland, Ph.D., as Chief Scientific Officer

Retrieved on:

Wednesday, December 7, 2022

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that it has appointed Ellen Cahir-McFarland, Ph.D., as its Chief Scientific Officer.

Key Points:

Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that it has appointed Ellen Cahir-McFarland, Ph.D., as its Chief Scientific Officer.
Her knowledge in immunology, MS, and translational medicine will be pivotal as we advance our Treg approach into the clinic, beginning with a breakthrough treatment for progressive MS, said Samantha Singer, M.S., M.B.A., president and chief executive officer of Abata.
I would also like to thank Andrea Van Elsas, who has served as our interim CSO since we formed the company.
Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases.